Lite Strategy, Inc.
For the period ended Jun 30, 2025. Filed Sep 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 26, 2025
LITS$0.96+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
(a)
- Consolidated Financial Statements
Reference is made to the Consolidated Financial Statements under Item 8. Consolidated Financial Statements and Supplementary Data in Part II hereof.
- Financial Statement Schedules
The Financial Statement Schedules have been omitted either because they are not required or because the information has been included in the consolidated financial statements or the notes thereto included in this Annual Report on Form 10-K.
- Exhibits
Exhibit Index
| Incorporated by Reference Herein | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | Schedule/Form | File No. | Exhibit | Filing Date |
| 3.1* · Amended and Restated Certificate of Incorporation of Lite Strategy, Inc. | |||||
| 3.2 | Sixth Amended and Restated Bylaws of MEI Pharma, Inc. adopted as of December 18, 2023 | 8-K | 001-41827 | 3.1 | December 22, 2023 |
| 4.1 | Specimen Stock Certificate | S-1 | 333-109129 | 4.1 | October 31, 2023 |
| 4.2 | Form of Warrant | 8-K | 000-50484 | 10.1 | May 16, 2018 |
| 4.3 | Description of Capital Stock of MEI Pharma, Inc. | 10-K | 000-50484 | 4.3 | September 9, 2020 |
| 4.4 | Description of MEI Common Stock | 10-K | 000-50484 | 4.4 | September 26, 2023 |
| 4.5 | Form of Pre-Funded Warrant | 8-K | 001-41827 | 4.1 | July 22, 2025 |
| 4.6 | Form of Placement Agent Warrant | 8-K | 001-41827 | 4.2 | July 22, 2025 |
| 4.7 | Form of GSR Pre-Funded Warrant | 8-K | 001-41827 | 4.3 | July 22, 2025 |
| 4.8 | Form of GSR Warrant | 8-K | 001-41827 | 4.4 | July 22, 2025 |
| 4.9 | Form of Advisory Warrant | 8-K | 001-41827 | 4.5 | July 22, 2025 |
| 4.10 | Form of Strategic Advisor Warrant | 8-K | 001-41827 | 4.6 | July 22, 2025 |
| 4.11 | Form of Warrant | 10-K | 000-50484 | 10.22 | September 23, 2023 |
| 10.1† | Amended and Restated 2008 Stock Omnibus Equity Compensation Plan (December 2023) | 10-Q | 001-41827 | 10.1 | May 9, 2024 |
| 10.2† | Form of Indemnification Agreement | 8-K | 000-50484 | 10.1 | August 29, 2011 |
| 10.3** | License Agreement, dated as of September 5, 2017, by and between MEI Pharma, Inc. and Presage Biosciences, Inc. | 10-Q | 000-50484 | 10.1 | November 8, 2017 |
| 10.4** | License, Development and Commercialization Agreement, dated as of October 31, 2018, by and between the Company and Kyowa Hakko Kirin Co., Ltd., now known as Kyowa Kirin Company | 10-Q | 000-50484 | 10.1 | February 7, 2019 |
| 10.5+ | License, Development and Commercialization Agreement, dated as of April 13, 2020, by and between the Company and Kyowa Kirin Co., Ltd. (formerly known as Kyowa Hakko Kirin Co., Ltd.) | 10-K | 000-50484 | 10.12 | September 2, 2021 |
| 10.6† | Employee Proprietary Information and Inventions Agreement between MEI Pharma, Inc. and Justin J. File, dated June 9, 2023 | 8-K | 000-50484 | 10.1 | June 13, 2023 |
| 10.7† | Amended and Restated Employment Agreement between MEI Pharma, Inc. and Justin J. File, dated March 3, 2025 | 8-K | 001-41827 | 10.1 | March 7, 2025 |
| 10.8† | Amended and Restated MEI Pharma, Inc. 2021 Inducement Grant Equity Compensation Plan | 8-K | 000-50484 | 10.3 | June 13, 2023 |
| 10.9 | Termination Agreement, by and between MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. (formerly known as Kyowa Hakko Kirin Co., Ltd.) dated as of July 14, 2023 | 8-K | 000-50484 | 10.1 | July 19, 2023 |
| 10.10 | Consulting Services Agreement, dated as of August 2, 2024, by and between MEI Pharma, Inc. and Richard G. Ghalie | 10-Q | 001-41827 | 10.4 | November 12, 2024 |
| 10.11 | Form of Securities Purchase Agreement, dated as of July 17, 2025, by and between MEI Pharma, Inc. and each Purchaser (as defined therein) | 8-K | 001-41827 | 10.1 | July 22, 2025 |
| 10.12 | Placement Agency Agreement, dated July 17, 2025, by and between MEI Pharma, Inc. and Titan Partners Group LLC, a division of American Capital Partners, LLC | 8-K | 001-41827 | 10.2 | July 22, 2025 |
| 10.13 | Form of Registration Rights Agreement, dated July 17, 2025, by and between MEI Pharma, Inc. and each Purchaser (as defined therein) | 8-K | 001-41827 | 10.3 | July 22, 2025 |
| 10.14 | Asset Management Agreement, dated July 22, 2025, by and between MEI Pharma, Inc. and GSR Strategies LLC | 8-K | 001-41827 | 10.4 | July 22, 2025 |
| 10.15 | Side Letter Agreement, dated July 22, 2025, by and between MEI Pharma, Inc. and GSR Strategies LLC | 8-K | 001-41827 | 10.5 | July 22, 2025 |
| 10.16 | Advisory Agreement, dated July 22, 2025, by and between MEI Pharma, Inc. and Green Dragon Investments LLC | 8-K | 001-41827 | 10.6 | July 22, 2025 |
| 10.17 | Strategic Advisor Agreement, dated July 22, 2025, by and between Green Grass Ventures | 8-K | 001-41827 | 10.7 | July 22,2025 |
| 10.18 | Master Loan Agreement, dated September 3, 2025, between BitGo Prime and MEI Pharma, Inc. | 8-K | 001-418247 | 10.1 | September 4, 2025 |
| 19* | Insider Trading Policy | ||||
| 23.1* | Consent of Deloitte & Touche LLP Independent Registered Public Accounting Firm | ||||
| 31.1* | Certification of Principal Executive and Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.1* | Certification of Principal Executive Officer and Principal Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C 1350). | ||||
| 97 | MEI Pharma, Inc. Clawback Policy | 10-K | 001-41827 | 97 | September 19, 2024 |
| 101INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | ||||
| 104 | Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the XBRL document. | ||||
| * | Filed herewith |
|---|---|
| ** | Portions of this exhibit have been redacted pursuant to a confidential treatment request filed with the Securities and Exchange Commission. |
| + | Portions of this exhibit have been omitted in accordance with Item 601(a)(6) and Item 601(b)(10) of Regulation S-K because such information (i) is not material and (ii) is the type that the registrant treats as private or confidential. |
| † | Each marked exhibit is a management contract or a compensatory plan, contract or arrangement in which a director or executive officer of the registrant participates or has participated. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.